KING OF PRUSSIA, PA — SEED Therapeutics Inc. has announced the appointment of Dr. Bill Desmarais, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, marking a critical addition to the company’s executive leadership. This strategic hire comes as SEED continues to advance its proprietary RITE3™ Targeted Protein Degradation (TPD) platform and prepares to launch new clinical trials targeting oncology, neurodegeneration, and immunology.
“Bill’s appointment comes at a pivotal time as SEED advances its differentiated pipeline into clinical trials and expands global strategic partnerships,” said Dr. Lan Huang, Co-Founder, Chairman, and CEO of SEED. “His extensive experience in high-impact transactions and strategic licensing will strengthen SEED’s ability to accelerate breakthrough therapies. This appointment underscores SEED’s commitment to delivering transformative treatments for patients, partners, and shareholders in 2025 and beyond.”
Dr. Desmarais brings over 20 years of leadership in finance and business development within the biopharma and biotech sectors. Notable achievements in his career include leading business development efforts at Momenta Pharmaceuticals, culminating in the company’s $6.5 billion acquisition by Johnson & Johnson. He has also held executive roles at Alchemab Therapeutics and TScan Therapeutics and spent over a decade at Eli Lilly and Company in corporate business development and global partnerships. Dr. Desmarais earned a Ph.D. in Biophysics and Structural Biology from Brandeis University, an MBA from the MIT Sloan School of Management, and a B.S. in Biology from Purdue University.
“I am excited to join SEED at this transformative moment, working alongside an exceptional team of leaders and innovators,” said Dr. Desmarais. “I look forward to collaborating with Dr. Lan Huang and her distinguished SEED Co-Founders—Nobel Laureate Avram Hershko and HHMI Investigators Michele Pagano and Ning Zheng. Together, we will advance SEED’s groundbreaking strategy, forge key alliances, and drive meaningful impact for patients and stakeholders worldwide.”
SEED Therapeutics is committed to pioneering innovative therapies through its RITE3™ TPD platform, which enables the precise targeting of disease-causing proteins for degradation. By combining world-class scientific leadership with cutting-edge technology, SEED aims to transform treatment outcomes for patients while fostering meaningful collaboration with industry partners.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.